Literature DB >> 28281102

Glutamine Addiction In Gliomas.

Javier Márquez1, Francisco J Alonso2, José M Matés2, Juan A Segura2, Mercedes Martín-Rufián2, José A Campos-Sandoval2.   

Abstract

Cancer cells develop and succeed by shifting to different metabolic programs compared with their normal cell counterparts. One of the classical hallmarks of cancer cells is their higher glycolysis rate and lactate production even in the presence of abundant O2 (Warburg effect). Another common metabolic feature of cancer cells is a high rate of glutamine (Gln) consumption normally exceeding their biosynthetic and energetic needs. The term Gln addiction is now widely used to reflect the strong dependence shown by most cancer cells for this essential nitrogen substrate after metabolic reprogramming. A Gln/glutamate (Glu) cycle occurs between host tissues and the tumor in order to maximize its growth and proliferation rates. The mechanistic basis for this deregulated tumor metabolism and how these changes are connected to oncogenic and tumor suppressor pathways are becoming increasingly understood. Based on these advances, new avenues of research have been initiated to find novel therapeutic targets and to explore strategies that interfere with glutamine metabolism as anticancer therapies. In this review, we provided an updated overview of glutamine addiction in glioma, the most prevalent type of brain tumor.

Entities:  

Keywords:  Anticancer therapy; Gliomas; Glutamate; Glutaminases; Glutamine-addiction; Glutaminolysis; Metabolic reprogramming

Mesh:

Substances:

Year:  2017        PMID: 28281102     DOI: 10.1007/s11064-017-2212-1

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  90 in total

Review 1.  Unique biology of gliomas: challenges and opportunities.

Authors:  Stacey Watkins; Harald Sontheimer
Journal:  Trends Neurosci       Date:  2012-06-08       Impact factor: 13.837

2.  Role of glutamine and neuronal glutamate uptake in glutamate homeostasis and synthesis during vesicular release in cultured glutamatergic neurons.

Authors:  Helle S Waagepetersen; Hong Qu; Ursula Sonnewald; Keiko Shimamoto; Arne Schousboe
Journal:  Neurochem Int       Date:  2005-07       Impact factor: 3.921

Review 3.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

4.  Identification of two human glutaminase loci and tissue-specific expression of the two related genes.

Authors:  J C Aledo; P M Gómez-Fabre; L Olalla; J Márquez
Journal:  Mamm Genome       Date:  2000-12       Impact factor: 2.957

5.  The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type.

Authors:  Mariia O Yuneva; Teresa W M Fan; Thaddeus D Allen; Richard M Higashi; Dana V Ferraris; Takashi Tsukamoto; José M Matés; Francisco J Alonso; Chunmei Wang; Youngho Seo; Xin Chen; J Michael Bishop
Journal:  Cell Metab       Date:  2012-02-08       Impact factor: 27.287

6.  Influence of glutamine on the growth of human glioma and medulloblastoma in culture.

Authors:  G Dranoff; G B Elion; H S Friedman; G L Campbell; D D Bigner
Journal:  Cancer Res       Date:  1985-09       Impact factor: 12.701

Review 7.  Glutaminase: a multifaceted protein not only involved in generating glutamate.

Authors:  Javier Márquez; Amada R López de la Oliva; José M Matés; Juan A Segura; Francisco J Alonso
Journal:  Neurochem Int       Date:  2006-03-03       Impact factor: 3.921

8.  Autocrine glutamate signaling promotes glioma cell invasion.

Authors:  Susan A Lyons; W Joon Chung; Amy K Weaver; Toyin Ogunrinu; Harald Sontheimer
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

9.  Mammalian glutaminase Gls2 gene encodes two functional alternative transcripts by a surrogate promoter usage mechanism.

Authors:  Mercedes Martín-Rufián; Marta Tosina; José A Campos-Sandoval; Elisa Manzanares; Carolina Lobo; J A Segura; Francisco J Alonso; José M Matés; Javier Márquez
Journal:  PLoS One       Date:  2012-06-05       Impact factor: 3.240

10.  Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia.

Authors:  Daniel Herranz; Alberto Ambesi-Impiombato; Jessica Sudderth; Marta Sánchez-Martín; Laura Belver; Valeria Tosello; Luyao Xu; Agnieszka A Wendorff; Mireia Castillo; J Erika Haydu; Javier Márquez; José M Matés; Andrew L Kung; Stephen Rayport; Carlos Cordon-Cardo; Ralph J DeBerardinis; Adolfo A Ferrando
Journal:  Nat Med       Date:  2015-09-21       Impact factor: 53.440

View more
  29 in total

Review 1.  SOX1 Is a Backup Gene for Brain Neurons and Glioma Stem Cell Protection and Proliferation.

Authors:  Kouminin Kanwore; Xiao-Xiao Guo; Ayanlaja Abiola Abdulrahman; Piniel Alphayo Kambey; Iqra Nadeem; Dianshuai Gao
Journal:  Mol Neurobiol       Date:  2021-01-22       Impact factor: 5.590

2.  Provocative Question: Should Ketogenic Metabolic Therapy Become the Standard of Care for Glioblastoma?

Authors:  Thomas N Seyfried; Laura Shelton; Gabriel Arismendi-Morillo; Miriam Kalamian; Ahmed Elsakka; Joseph Maroon; Purna Mukherjee
Journal:  Neurochem Res       Date:  2019-04-25       Impact factor: 3.996

3.  Metabolic Evaluation of MYCN-Amplified Neuroblastoma by 4-[18F]FGln PET Imaging.

Authors:  Chao Li; Shuo Huang; Jun Guo; Cheng Wang; Zhichao Huang; Ruimin Huang; Liang Liu; Sheng Liang; Hui Wang
Journal:  Mol Imaging Biol       Date:  2019-12       Impact factor: 3.488

Review 4.  Glutamine Imaging: A New Avenue for Glioma Management.

Authors:  S Ekici; J A Nye; S G Neill; J W Allen; H-K Shu; C C Fleischer
Journal:  AJNR Am J Neuroradiol       Date:  2021-11-04       Impact factor: 3.825

5.  Crosstalk Between the Gut and Brain: Importance of the Fecal Microbiota in Patient With Brain Tumors.

Authors:  Yuping Li; Haixiao Jiang; Xiaolin Wang; Xiaoguang Liu; Yujia Huang; Zhiyao Wang; Qiang Ma; Lun Dong; Yajie Qi; Hengzhu Zhang; Guangyu Lu
Journal:  Front Cell Infect Microbiol       Date:  2022-06-17       Impact factor: 6.073

Review 6.  Plasticity in Glioma Stem Cell Phenotype and Its Therapeutic Implication.

Authors:  Yasuo Iwadate
Journal:  Neurol Med Chir (Tokyo)       Date:  2017-11-13       Impact factor: 1.742

Review 7.  The emerging role and targetability of the TCA cycle in cancer metabolism.

Authors:  Nicole M Anderson; Patrick Mucka; Joseph G Kern; Hui Feng
Journal:  Protein Cell       Date:  2017-07-26       Impact factor: 14.870

8.  HIV infection and latency induce a unique metabolic signature in human macrophages.

Authors:  Paul Castellano; Lisa Prevedel; Silvana Valdebenito; Eliseo A Eugenin
Journal:  Sci Rep       Date:  2019-03-08       Impact factor: 4.379

Review 9.  Targeting Glutamine Metabolism for Cancer Treatment.

Authors:  Yeon-Kyung Choi; Keun-Gyu Park
Journal:  Biomol Ther (Seoul)       Date:  2018-01-01       Impact factor: 4.634

Review 10.  Mitochondria Targeting as an Effective Strategy for Cancer Therapy.

Authors:  Poorva Ghosh; Chantal Vidal; Sanchareeka Dey; Li Zhang
Journal:  Int J Mol Sci       Date:  2020-05-09       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.